Home › Companies › Arcus Biosciences, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Dietmar Berger, M.D., Ph.D. | 85,949,508 | -- | -- | 18,338,022 | 13,573,227 | Majority: yes |
| Elect Director: David Lacey, M.D. | 85,974,583 | -- | -- | 18,312,947 | 13,573,227 | Majority: yes |
| Elect Director: Nicole Lambert | 92,653,341 | -- | -- | 11,634,189 | 13,573,227 | Majority: yes |
| Elect Director: Johanna Mercier | 85,941,754 | -- | -- | 18,345,776 | 13,573,227 | Majority: yes |
| Proposal 2: The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: | 112,905,582 | 4,767,430 | 187,745 | -- | -- | Majority: yes |
| Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: | 94,920,421 | 9,337,368 | 29,741 | -- | 13,573,227 | Majority: yes |
Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.
Each item below shows how the 250 asset managers that disclosed a Arcus Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Proposal 3: The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement:”): 94,920,421 for, 9,337,368 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,773,162 outstanding shares: 75% for, 7% against (83% of the company cast a for/against vote).
The 249 asset managers below cast 92% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 31,424,760 | 0 | 0 | 0 | For |
| BlackRock | 13,817,888 | 23,495 | 0 | 0 | For |
| Vanguard | 13,140,223 | 12,159 | 0 | 0 | For |
| Wellington | 5,771,705 | 0 | 0 | 0 | For |
| State Street | 5,281,519 | 18,905 | 0 | 0 | For |
| Fidelity | 4,330,715 | 0 | 0 | 0 | For |
| MONTANOVA CAPITAL, LLC | 3,605,278 | 0 | 0 | 0 | For |
| Woodline Partners LP | 3,135,709 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,256,471 | 0 | 0 | 0 | For |
| SAMLYN CAPITAL, LLC | 0 | 1,908,245 | 0 | 0 | Against |
| Charles Schwab | 1,667,112 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 1,654,754 | 0 | 0 | Against |
| Siren, L.L.C. | 1,395,000 | 0 | 0 | 0 | For |
| Trails Edge Capital Partners, LP | 1,134,935 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 1,077,276 | 35,078 | 0 | 0 | For |
| Logos Global Management LP | 0 | 1,100,000 | 0 | 0 | Against |
| Aberdeen | 0 | 1,032,417 | 0 | 0 | Against |
| Candriam S.C.A. | 0 | 790,613 | 0 | 0 | Against |
| Northern Trust | 726,063 | 11,006 | 0 | 0 | For |
| MARSHALL WACE, LLP | 727,349 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 494,591 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 477,819 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 443,829 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 434,868 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 423,889 | 0 | 0 | 0 | For |
Showing the 25 largest of 249 asset managers. See all 249 in the interactive database.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: David Lacey, M.D.”): 85,974,583 for, 18,312,947 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,773,162 outstanding shares: 68% for, 15% withheld (83% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (27,294,920 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,445,214 | 0 | 132 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 8,245 | 0 | 3,649,002 | 0 | Abstain |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 768,350 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 379,100 | 0 | Abstain |
| Aberdeen | 0 | 0 | 266,041 | 0 | Abstain |
| First Trust | 0 | 0 | 241,689 | 0 | Abstain |
| TIAA | 0 | 0 | 210,638 | 0 | Abstain |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 58,100 | 0 | For |
| Jackson National | 0 | 0 | 149,532 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 129,106 | 0 | Abstain |
| Invesco | 0 | 0 | 100,687 | 0 | Abstain |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 66,723 | 0 | 11,406 | 0 | For |
| Thrivent | 0 | 0 | 77,528 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 74,700 | 0 | Abstain |
| Bridge Builder Trust | 22,058 | 0 | 51,408 | 0 | Abstain |
| Principal | 0 | 0 | 72,189 | 0 | Abstain |
| ProShares | 0 | 0 | 66,038 | 0 | Abstain |
| Empower | 0 | 0 | 60,027 | 0 | Abstain |
| Lincoln Financial | 0 | 0 | 58,201 | 0 | Abstain |
| Northern Trust | 0 | 0 | 49,426 | 0 | Abstain |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Dietmar Berger, M.D., Ph.D.”): 85,949,508 for, 18,338,022 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,773,162 outstanding shares: 68% for, 15% withheld (83% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (30,355,930 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,410,256 | 0 | 35,090 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,646,532 | 0 | 10,715 | 0 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 768,350 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 379,100 | 0 | Abstain |
| Aberdeen | 0 | 0 | 266,041 | 0 | Abstain |
| First Trust | 0 | 0 | 241,689 | 0 | Abstain |
| TIAA | 0 | 0 | 210,638 | 0 | Abstain |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 58,100 | 0 | For |
| Jackson National | 130,963 | 0 | 18,569 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 129,106 | 0 | Abstain |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 0 | 0 | 84,214 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 78,129 | 0 | Abstain |
| Thrivent | 0 | 0 | 77,528 | 0 | Abstain |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 22,058 | 0 | 51,408 | 0 | Abstain |
| Principal | 0 | 0 | 72,189 | 0 | Abstain |
| ProShares | 0 | 0 | 66,038 | 0 | Abstain |
| Empower | 0 | 0 | 60,027 | 0 | Abstain |
| Lincoln Financial | 51,100 | 0 | 7,101 | 0 | For |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 3 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Johanna Mercier”): 85,941,754 for, 18,345,776 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,773,162 outstanding shares: 68% for, 15% withheld (83% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (30,355,930 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,410,256 | 0 | 35,090 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,646,532 | 0 | 10,715 | 0 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 768,350 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 379,100 | 0 | Abstain |
| Aberdeen | 0 | 0 | 266,041 | 0 | Abstain |
| First Trust | 0 | 0 | 241,689 | 0 | Abstain |
| TIAA | 0 | 0 | 210,638 | 0 | Abstain |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 58,100 | 0 | For |
| Jackson National | 130,963 | 0 | 18,569 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 129,106 | 0 | Abstain |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 0 | 0 | 84,214 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 78,129 | 0 | Abstain |
| Thrivent | 0 | 0 | 77,528 | 0 | Abstain |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 22,058 | 0 | 51,408 | 0 | Abstain |
| Principal | 0 | 0 | 72,189 | 0 | Abstain |
| ProShares | 0 | 0 | 66,038 | 0 | Abstain |
| Empower | 0 | 0 | 60,027 | 0 | Abstain |
| Lincoln Financial | 51,100 | 0 | 7,101 | 0 | For |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 3 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Nicole Lambert”): 92,653,341 for, 11,634,189 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,773,162 outstanding shares: 74% for, 9% withheld (83% of the company cast a for/withheld vote).
The 71 asset managers below cast 100% of the shares they voted on this item FOR (31,316,916 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,445,259 | 0 | 87 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,652,652 | 0 | 4,595 | 0 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 768,350 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 379,100 | 0 | Abstain |
| Aberdeen | 0 | 0 | 266,041 | 0 | Abstain |
| First Trust | 0 | 0 | 241,689 | 0 | Abstain |
| TIAA | 0 | 0 | 210,638 | 0 | Abstain |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 119,456 | 0 | 58,100 | 0 | For |
| Jackson National | 0 | 0 | 149,532 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,106 | 0 | 0 | 0 | For |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 66,723 | 0 | 11,406 | 0 | For |
| Thrivent | 0 | 0 | 77,528 | 0 | Abstain |
| BNY Mellon | 0 | 0 | 74,700 | 0 | Abstain |
| Bridge Builder Trust | 22,058 | 0 | 51,408 | 0 | Abstain |
| Principal | 0 | 0 | 72,189 | 0 | Abstain |
| ProShares | 0 | 0 | 66,038 | 0 | Abstain |
| Empower | 0 | 0 | 60,027 | 0 | Abstain |
| Lincoln Financial | 51,100 | 0 | 7,101 | 0 | For |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Arcus Biosciences, Inc.’s own tally for this item (“Proposal 2: The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year endi”): 112,905,582 for, 4,767,430 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 125,773,162 outstanding shares: 90% for, 4% against (94% of the company cast a for/against vote).
The 71 asset managers below cast 97% of the shares they voted on this item FOR (32,472,026 for, 905,332 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,433,220 | 12,126 | 0 | 0 | For |
| BlackRock | 10,028,541 | 0 | 0 | 0 | For |
| State Street | 3,657,068 | 179 | 0 | 0 | For |
| Fidelity | 3,158,497 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 768,350 | 0 | 0 | Against |
| Delaware/Macquarie | 379,100 | 0 | 0 | 0 | For |
| Aberdeen | 266,041 | 0 | 0 | 0 | For |
| First Trust | 241,689 | 0 | 0 | 0 | For |
| TIAA | 210,638 | 0 | 0 | 0 | For |
| Hartford | 182,809 | 0 | 0 | 0 | For |
| Equitable | 177,556 | 0 | 0 | 0 | For |
| Jackson National | 149,532 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 136,319 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 129,106 | 0 | 0 | 0 | For |
| Invesco | 100,687 | 0 | 0 | 0 | For |
| Tema ETF Trust | 84,214 | 0 | 0 | 0 | For |
| Prudential/PGIM | 78,129 | 0 | 0 | 0 | For |
| Thrivent | 77,528 | 0 | 0 | 0 | For |
| BNY Mellon | 74,700 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,466 | 0 | 0 | 0 | For |
| Principal | 72,189 | 0 | 0 | 0 | For |
| ProShares | 66,038 | 0 | 0 | 0 | For |
| Empower | 60,027 | 0 | 0 | 0 | For |
| Lincoln Financial | 58,201 | 0 | 0 | 0 | For |
| Northern Trust | 49,426 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
Ranked by the number of Arcus Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 125,773,162 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 24.99% |
| 2 | BlackRock | 11.01% |
| 3 | Vanguard | 10.46% |
| 4 | Wellington | 4.59% |
| 5 | State Street | 4.21% |
| 6 | Fidelity | 3.44% |
| 7 | MONTANOVA CAPITAL, LLC | 2.87% |
| 8 | Woodline Partners LP | 2.49% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.79% |
| 10 | SAMLYN CAPITAL, LLC | 1.52% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Gilead Sciences, Inc. | 24.99% | 13D |
| BlackRock, Inc. | 10.13% | 13G |
| Vanguard Group | 6.33% | 13F |
| Wellington Management | 4.84% | 13F |
| State Street | 4.30% | 13F |
| Terry Rosen, Ph.D. | 2.06% | DEF14A |
| Geode Capital | 1.79% | 13F |
| Dimensional Fund Advisors | 1.13% | 13F |
| Citadel Advisors | 1.13% | 13F |
| Morgan Stanley | 0.96% | 13F |
Percentages above are of 125,773,162 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Arcus Biosciences, Inc.'s shareholder meeting held 2026-06-11, in the 2025-2026 proxy season, 250 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,979 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.
Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).